DNlite-DKD uPTM-FetA ELISA Kit
Identify patients who are at a higher risk for progression of DKD
Current diagnosis of Diabetic Kidney Disease (DKD) relies on test of Urine Albuminuria-to-Creatinine Ratio (UACR) and estimation of GFR (eGFR), but these cannot meet the required sensitivity and specificity. Furthermore, both UACR and eGFR cannot predict and identify DKD patients who will progress, it is crucial for DKD management.
DNlite-IVD103 test is a patented and clinically validated non-invasive urine test for DKD Management. Patients in early stage of diabetes or with DKD are strongly recommended to manage the progression by DNlite test.
Take Action BEFORE DKD Onset
Precision
Precise management of DKD
Prediction
As newer therapies emerge, the ability to stratify patients is valuable.
Prognosis
Improved ability to prognosticate a patient’s DKD course.
Prevention
Earlier implementation of therapies to more aggressively control and even halt the progression of DKD.
DNlite-IVD103: Enable Earlier Risk Assessment and Prevention
A better predictor to identify patients who are at higher risk for DKD progression
Featured Publications
In a study published in the International Journal of Advances in Nephrology Research, researchers used an ELISA-based assay to measure levels of post-translationally modified Fetuin-A (PTM-Fetuin-A) in urine to assess its potential as a novel, non-invasive biomarker for early detection and monitoring of diabetic kidney disease. The ELISA results showed significant correlations with traditional indicators of renal function, demonstrating its value for identifying early kidney function decline beyond conventional markers.
In a study published in American Journal of Nephrology, investigators measured urinary post-translationally modified Fetuin-A (uPTM-FetA) using a CE-IVD ELISA assay (Human uPTM3-DKD ELISA kit) to quantify urinary biomarker levels in type 2 diabetes patients. Higher uPTM-FetA, normalized to creatinine, was strongly associated with progressive decline in kidney function over follow-up across two independent cohorts, highlighting the ELISA’s value in evaluating risk of renal deterioration beyond conventional clinical markers.
